https://finance.yahoo.com/news/adaptimmune-announces-clinical-responses-across-110000773.html
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial